Ann Cleverly
Impact in
- Oncology top 2%
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism
Papers in
-
- TGF-β signaling in diseases 28
- Oncology 24
- Pancreatic and Hepatic Oncology Research 14
- Colorectal Cancer Treatments and Studies 10
- Cancer Treatment and Pharmacology 3
- Co-authors
- Ivelina Gueorguieva (30 shared papers)Michael Lahn (17 shared papers)Karim A. Benhadji (18 shared papers)Shawn T. Estrem (8 shared papers)Michael Lahn (21 shared papers)Susan C. Guba (6 shared papers)Anja J. Stauber (2 shared papers)Jordi Rodón (10 shared papers)
- Journals
- Journal of Clinical Oncology (18 papers)Clinical Cancer Research (3 papers)Cancer Chemotherapy and Pharmacology (3 papers)Biomarkers (2 papers)PLoS ONE (2 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Ann Cleverly
54 papers receiving 2.6k citations
Ann Cleverly's Hit Papers
Peers
Comparison fields: 5 of 94
- Oncology 1.4k
- Cancer Research 372
- Hepatology 184
- Immunology 514
- Genetics 226
Countries citing papers authored by Ann Cleverly
This map shows the geographic impact of Ann Cleverly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Cleverly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Cleverly more than expected).
Fields of papers citing papers by Ann Cleverly
This network shows the impact of papers produced by Ann Cleverly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Cleverly. The network helps show where Ann Cleverly may publish in the future.
Co-authors
The 25 scholars most cited alongside Ann Cleverly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway Hit paper breakdown → | 2015 | 462 |
| 2 | 2018 | 233 | |
| 3 | 2016 | 208 | |
| 4 | 2019 | 203 | |
| 5 | 2014 | 200 | |
| 6 | 2019 | 121 | |
| 7 | 2020 | 100 | |
| 8 | 2014 | 94 | |
| 9 | 2014 | 82 | |
| 10 | 2019 | 78 | |
| 11 | 2013 | 67 | |
| 12 | 2019 | 65 | |
| 13 | 2008 | 54 | |
| 14 | 2008 | 52 | |
| 15 | 2020 | 49 | |
| 16 | 2014 | 42 | |
| 17 | 2014 | 37 | |
| 18 | 2021 | 36 | |
| 19 | 1991 | 35 | |
| 20 | 2016 | 33 |
About Ann Cleverly
Ann Cleverly is a scholar working on Molecular Biology, Oncology, Genetics, Pulmonary and Respiratory Medicine and Cancer Research, having authored 54 papers that have together received 2.6k indexed citations. Recurring topics across this work include TGF-β signaling in diseases (28 papers), Pancreatic and Hepatic Oncology Research (14 papers), Colorectal Cancer Treatments and Studies (10 papers), Glioma Diagnosis and Treatment (7 papers), Cancer, Hypoxia, and Metabolism (5 papers), Genetic factors in colorectal cancer (4 papers), Renal cell carcinoma treatment (3 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (372 citations), Hepatology (184 citations), Immunology (514 citations) and Genetics (226 citations). Ann Cleverly has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Ivelina Gueorguieva, Michael Lahn, Karim A. Benhadji, Shawn T. Estrem, Michael Lahn, Susan C. Guba, Anja J. Stauber, Jordi Rodón, Claire Smith and Kyla Driscoll. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Chemotherapy and Pharmacology, Biomarkers and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.